As at May 3, 2024, the ALKS stock has a PE ratio of 9.18. This is based on the current EPS of $2.62 and the stock price of $24.05 per share. A decrease of 62% has been recorded in the P/E ratio compared to the average of 24.1 of the last 4 quarters.
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 12.96 | N/A |
| 2022 | N/A | N/A |
| 2021 | N/A | N/A |
| 2020 | N/A | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
ALKS's PE ratio is lower than its peer stocks JNJ and AZN. Alkermes is presently trading at a lower PE ratio (9.18) than its peer group average of 33.33.
| Stock name | PE ratio | Market cap |
|---|---|---|
| ALKS Alkermes plc | 9.18 | $4.07B |
| JNJ Johnson & Johnson | 9.78 | $359.25B |
| NVS Novartis AG | 13.13 | $198.47B |
| AZN Astrazeneca plc | 37.24 | $236.71B |
| PFE Pfizer Inc | 73.18 | $157.04B |
| BMY Bristol Myers Squibb Co | N/A | $89.17B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $15.67B |
The price to earnings ratio for ALKS stock as of May 3, 2024, stands at 9.18.
A company with a lower PE ratio may indicate that the market has lower growth expectations for the company's future earnings.
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (May 3, 2024), Alkermes's stock price is $24.05. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $2.62. Therefore, Alkermes's P/E ratio for today is 9.18. PE RATIO(9.18) = STOCK PRICE($24.05) / TTM EPS($2.62)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.